SuperworthGlobus Medical GMED
- Market cap
- $10.9B
- PE
- 20.8×
- 10y median 37.4×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.5×
- EV/EBIT
- 16.3×
- Revenue, 12 months
- $3.1B
- +20% on a year ago
- Net margin
- 17.0%
- Free cash flow yield
- 6.9%
Globus Medical trades at 20.8× trailing earnings, cheaper than 94% of the last ten years. Revenue was $3.1B over the last twelve months, up 20% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $383.6M+51% | $616.5M+125% | $606.7M+119% | $629.7M+116% | $625.7M+63% | $657.3M+7% | $598.1M−1% | $745.3M+18% | $769M+23% | $826.4M+26% | $759.9M+27% | $789.6M+6% | |
| Cost of revenue | $383.2M+485% | $265.5M+276% | $598.7M+745% | $580.1M+659% | $577.6M+51% | $597M+125% | $501.1M−16% | $669.2M+15% | $631.7M+9% | $657.1M+10% | $609.5M+22% | $607.2M−9% |
| Gross profit | $404K−100% | $351M+72% | $8M−96% | $49.6M−77% | $48.1M+11805% | $60.3M−83% | $97M+1113% | $76.1M+53% | $137.4M+186% | $169.3M+181% | $150.4M+55% | $182.4M+140% |
| R&D | $29.3M+57% | $52.3M+168% | $57.3M+172% | $37.7M+77% | $35.4M+21% | $33.4M−36% | $33.1M−42% | $40M+6% | $38.1M+8% | $36.2M+8% | $36.5M+10% | $36.3M−9% |
| SG&A | $156.2M+47% | $244.7M+107% | $248.7M+103% | $239.5M+99% | $240.1M+54% | $253.2M+4% | $242.8M−2% | $303.6M+27% | $313.6M+31% | $318.5M+26% | $297.8M+23% | $286.8M−6% |
| $404K−99% | $10.1M−81% | $8M−86% | $49.6M−25% | $48.1M+11805% | $60.3M+495% | $97M+1113% | $76.1M+53% | $137.4M+186% | $169.3M+181% | $150.4M+55% | $182.4M+140% | |
| Pre-tax income | $2.5M−96% | $25M−60% | −$8.6M | $47.6M−36% | $57M+2150% | $24.7M−1% | $103.7M | $188.2M+296% | $144M+153% | $169.2M+586% | $157.1M+52% | $189.8M+1% |
| $1.5M−89% | $10M−17% | −$1.4M | $15.8M−7% | $5.2M+238% | −$1.8M | $28.2M | −$14.7M | $25M+382% | $28.6M | $32.8M+16% | $38.2M | |
| Net income | $998K−98% | $15M−70% | −$7.1M | $31.8M−45% | $51.8M+5094% | $26.5M+76% | $75.5M | $202.8M+539% | $119M+130% | $140.6M+430% | $124.3M+65% | $151.6M−25% |
| $0.01−98% | $0.12−76% | −$0.05 | $0.23−60% | $0.38+3700% | $0.19+58% | $0.54 | $1.49+548% | $0.88+132% | $1.03+442% | $0.90+67% | $1.10−26% | |
| 115.2M+14% | 128.2M+25% | 135.4M+32% | 137M+35% | 138.1M+20% | 139.7M+9% | 139.8M+3% | 136.5M−0% | 135.4M−2% | 136.6M−2% | 138.2M−1% | 137.4M+1% |
Revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them. 11 periods, Q3 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. Q4 FY11: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.214). 14 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Globus Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | 3.5× | +20% | 17.0% | |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | 2.7× | +4% | 10.0% | |
| PODDInsulet | $10.3B | 27.9× | 63.0× | 3.4× | +29% | 12.3% | |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | 2.7× | +5% | 13.5% | |
| PENPenumbra | $12.8B | 79.7× | 197× | 8.5× | +18% | 10.7% | |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | 1.7× | −1% | 17.3% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| Peer median | $8.7B | 27.4× | 45.5× | 3.5× | +5% | 11.8% |
Investors who own it
Investors we follow who held Globus Medical at the end of Jun 30, 2026, from their 13F filings.
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)0.0% of portfolio
More on Globus Medical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 23Medical instruments and supplies stocks cheapest against their own PE history
- #9of 92Healthcare stocks cheapest against their own PE history
- #8of 80Medical instruments and supplies stocks with the highest profit margins
- #10of 45Medical instruments and supplies stocks with the highest free cash flow yield
- #9of 33Medical instruments and supplies stocks with the fastest earnings growth
- #10of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .